Prudential Financial
CTKB icon

Prudential Financial’s Cytek Biosciences CTKB Stock Holding History

Prudential Financial’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$514K Buy
117,597
+10,740
+10% +$50.7K ﹤0.01% 1856
2025
Q4 		$540K Sell
106,857
-5,810
-5% -$27K ﹤0.01% 1809
2025
Q3 		$391K Hold
112,667
– – ﹤0.01% 2024
2025
Q2 		$383K Buy
112,667
+6,285
+6% +$20.9K ﹤0.01% 2032
2025
Q1 		$427K Sell
106,382
-67,000
-39% -$347K ﹤0.01% 1891
2024
Q4 		$1.13M Buy
173,382
+63,600
+58% +$379K ﹤0.01% 1530
2024
Q3 		$608K Buy
109,782
+6,700
+6% +$38K ﹤0.01% 2132
2024
Q2 		$575K Sell
103,082
-9,150
-8% -$55K ﹤0.01% 2108
2024
Q1 		$753K Sell
112,232
-1,345
-1% -$10.6K ﹤0.01% 1974
2023
Q4 		$1.04M Sell
113,577
-2,610
-2% -$16.4K ﹤0.01% 1801
2023
Q3 		$641K Buy
116,187
+16,000
+16% +$128K ﹤0.01% 1964
2023
Q2 		$856K Buy
+100,187
New +$899K ﹤0.01% 1884

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial's CTKB Position: Q1 2026 in Review

Prudential Financial increased its Cytek Biosciences (CTKB) stake by 10% in Q1 2026, buying an estimated $50.7K and bringing the position to 117,597 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Prudential Financial first reported a position in CTKB in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.13M in Q4 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Prudential Financial held 117,597 shares of Cytek Biosciences worth $514K as of Q1 2026.
  • Prudential Financial bought 10,740 Cytek Biosciences shares in Q1 2026, an estimated $50.7K.
  • Cytek Biosciences made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1856 holding.
  • Prudential Financial first reported a position in Cytek Biosciences in Q2 2023 and has held it in 12 quarters since.
  • Prudential Financial's Cytek Biosciences position peaked at $1.13M in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.